RPG Life Sciences
- Market cap
- ₹ 4,325 Cr.
- P/E
- 37x
- P/B
- 7.6x
- 52-week range
- 1,733 – 3,127.8
- ROE
- 19%
- ROCE
- 26%
- Dividend yield
- 0.9%
- Debt / equity
- 0.03
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
RPG Life Sciences Limited is an India-based research-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations, and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has a presence in nephrology, oncology, rheumatology, cardiology, respiratory, pain management, vitamins & minerals, gastroenterology, and gynecology & pediatrics. The International Formulations business operates in the generics and branded generics space across Canada, Europe, Australia, New Zealand, and South America. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Naprosyn, Teristrong, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →RPG Life Sciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)37 against a typical 33.2: pricier than most peers (1st = cheapest).126th of 220
- Sales growth+16% against a typical +15.6% from a year earlier.98th of 197
- Profit growth+19.2% against a typical +18.9% from a year earlier.80th of 160
- Share price, 3 months0% against a typical −1.8%.90th of 200
- Size₹ 4,325.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).55th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A+ | Stable | 11 Sep 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 11 Sep 2026 | Reaffirmed | [ICRA]A+ | — | ICRA | ₹ 94.45 Cr. | |
| 7 Aug 2026 | Rating action | [ICRA]A+ | — | ICRA | ₹ 94.45 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 29 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 28 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 Apr 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 27 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 17 Oct 2025 | Financial Results | RPG Life Sciences Limited informed that the meeting of the Board of Directors of the Company is scheduled on 17/10/2025 to consider and approve Unaudited Financial Results for the quarter and half year ended September 30, 2025. |
| 25 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 28 Apr 2025 | Financial Results/Dividend | Pursuant to the provisions of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that a meeting of the Board of Directors of the Company is scheduled on Monday, April 28, 2025, inter-alia, to: 1. Consider and approve the Audited Financial Results for the quarter and financial year ended March 31, 2025.2. Recommend dividend, if any, on Equity Shares of the Company for the financial year ended March 31, 2025. Further, pursuant to the Code of Fair Disclosure, Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders of the Company and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in Securities of the Company by Designated Persons and their immediate relatives, is closed from April 1, 2025 and will continue to remain closed till 48 hours after declaration of results on April 28, 2025. |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating Profit | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 | 39 | 40 | 33 | 44 |
| OPM % | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% | 21% | 22% | 19% | 22% |
| Other Income | 2 | 2 | 2 | 2 | −25 | 3 | 115 | 5 | 16 | −5 | 13 | 4 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% | 25% | 24% | 26% | 26% |
| Net Profit | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS in Rs | 15.64 | 16 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.9 | 22.28 | 13.38 | 18.08 | 18.48 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 10%
- 5 Years
- 13%
- 3 Years
- 11%
- TTM
- 12%
- 10 Years
- 25%
- 5 Years
- 22%
- 3 Years
- 17%
- TTM
- 13%
- 10 Years
- 20%
- 5 Years
- 39%
- 3 Years
- 30%
- TTM
- —
- 10 Years
- 20%
- 5 Years
- 23%
- 3 Years
- 23%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| RPG Life Sciences | ₹ 2,854.00 | ₹ 4,325 Cr. | 37x | 7.6x | 19% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Amol Lone
- Chief Financial Officer
- Sheetal Gaba
- Chief Human Resources Officer
- Rajesh Shirambekar
- Head - Legal, Compliance Officer, Company Secretary
- Mahesh Narayanaswamy
- Vice President - Finance
- Ashok Nair
- Managing Director, Director
Prices are delayed and for information only. Nothing on this page is investment advice.